Closing
Do thiazolidinediones improve lipids versus placebo?
Mostly studied in type 2 & unspecified diabetes. Also asked against other treatments.
Not modeled yetTrial evidence exists, but no mechanistic model yetWithout a model there is no decisive experiment to propose. Help build it. →
Where the evidence stands
Doubtful. So far, no trial evidence yet.
NoUnsureYes
- Belief
- 0.25 (range 0.10–0.70)
- Trials for
- 0
- Trials against
- 0
- Inconclusive
- 1
Already under way
- Protocol V: San Antonio Site Sub Study: Can Pioglitazone Block SGLT2 Inhibitor-induced Stimulation of Lipolysis, Ketone Production and Liver Glucose Production…NCT07056699 · recruiting · started 2026
- Randomized, Parallel Group, Dose Escalation Trial of Pioglitazone Versus Empagliflozin for Chronic Pancreatitis/Recurrent Acute Pancreatitis/Acute Pancreatitis…NCT06729996 · recruiting · started 2025
- Open-label, Double-arm, Controlled, Randomized, Multicentre Clinical Trial to Evaluate the Impact of Pharmacogenetic-guided Treatment in Patients With…NCT06851962 · active not recruiting · started 2025
- Evaluation of Pioglitazone and Empagliflozin Combination Therapy in Type 2 Diabetes Patients With Metabolic Dysfunction-Associated Fatty Liver DiseaseNCT06989723 · recruiting · started 2025
- Pioneering and Affordable Strategies to Prevent Progression of Prediabetes, Obesity and CV Risk in HispanicsNCT06446531 · recruiting · started 2024
The evidence so far
- Registered trials
- 58
- With posted results
- 18
- Published papers
- 3
Of 56 decided analyses: 15 favor thiazolidinediones, 25 find no difference, 16 favor the comparator.
Papers
- The effect of a dual combination of noninsulin antidiabetic drugs on lipids: a systematic review and network meta-analysis.Meta-analysis / systematic review · 2014
- Effect of glucagon-like peptide-1 receptor agonists on lipid profiles among type 2 diabetes: a systematic review and network meta-analysis.Meta-analysis / systematic review · 2015
- Homocysteine levels in women with polycystic ovary syndrome treated with metformin versus rosiglitazone: a randomized study.Trial report · 2005
Trials
- Safety and Efficacy of Exenatide Once Weekly Injection Versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients With Type 2 DiabetesNCT00676338 · 9 posted results
- Effects of a Pioglitazone/Metformin Fixed Combination in Comparison to Metformin in Combination With Glimepiride on Diabetic DyslipidemiaNCT00770653 · 6 posted results
- A Phase 3b, Double-Blind, Randomized Study to Determine the Efficacy and Safety of Pioglitazone HCl and Metformin HCl Fixed-Dose Combination Therapy Compared to Pioglitazone HCl Monotherapy and to Metformin HCl Monotherapy in the Treatment of Subjects With Type 2 DiabetesNCT00727857 · 63 posted results
- Modulation of Insulin Secretion and Insulin Sensitivity in Bangladeshi Type 2 Diabetic Subjects by an Insulin Sensitizer Pioglitazone and T2DM Association With PPARG Gene Polymorphism.NCT01589445 · 4 posted results
- Studies to Treat Or Prevent Pediatric Type 2 Diabetes (STOPP-T2D) Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Clinical TrialNCT00081328 · 2 posted results
- A Randomised Controlled Trial for People With Established Type 2 Diabetes During Ramadan: Canagliflozin (Invokana™) vs. Standard Dual Therapy Regimen: The 'Can Do Ramadan' StudyNCT02694263
- Effects of Insulin Sensitizers in Subjects With Impaired Glucose ToleranceNCT00108615
- A Long Term, Open Label, Randomised Study in Patients With Type 2 Diabetes, Comparing the Combination of Rosiglitazone and Either Metformin or Sulfonylurea With Metformin Plus Sulfonylurea on Cardiovascular Endpoints and GlycaemiaNCT00379769 · 3 posted results